Palvella Therapeutics reports Q3 results
Palvella Therapeutics reported a quarterly loss, according to the headline and available body fragment.
Related stories
Sempra Reports Third-Quarter 2026 Results, Updates EPS Guidance
Sempra reported strong third-quarter 2026 results and updated its 2026 GAAP EPS guidance range, guiding to the high end.
M impact | EQUITY | Nov 05, 2026, 01:02 PM UTC
Palvella Therapeutics Posts Q3 Loss of $1.70 a Share
M impact | EQUITY | Nov 05, 2026, 12:59 PM UTC
Vericel Reports Third-Quarter Results, Raises Full-Year Guidance
Vericel reported revenue growth of 26% to $85.4 million and a 179% increase in net income to $14.2 million.
M impact | EQUITY | Nov 05, 2026, 12:58 PM UTC
Sempra reports third-quarter revenue of $3.19B
M impact | EQUITY | Nov 05, 2026, 12:58 PM UTC
Real REMAX Group Q3 Revenue Rises 28%, Beats Estimates
M impact | EQUITY | Nov 05, 2026, 12:55 PM UTC
Sabre Posts Third-Quarter 2026 Earnings Materials on Investor Relations Website
Sabre said its third-quarter 2026 earnings materials are available on its Investor Relations website.
M impact | EQUITY | Nov 05, 2026, 12:55 PM UTC